Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* advanced measurable Non-Small Cell Lung Cancer (NSCLC);~* progressed after 1-2 prior chemotherapy;~* Eastern Cooperative Oncology Group (ECOG) 0-2;~* tissue available for future KRAS/ EGFR testing~Exclusion Criteria:~* prior Epidermal Growth Factor Receptor (EGFR) targeted therapy;~* active or untreated Central Nervous System (CNS) metastases;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): None
- B (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).